The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology Drugs at a Glance, Part 2: Psoriasis

Rheumatology Drugs at a Glance, Part 2: Psoriasis

May 17, 2019 • By Mary Choy, PharmD, BCGP, FASHP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Etanercept (Enbrel):15 injection

Drug class: DMARD, TNFi

You Might Also Like
  • Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis
  • Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis
  • Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4
Explore This Issue
May 2019

Boxed warning: Refer to *ISI (left)

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Warnings & Precautions

  • Do not start etanercept during an active infection. If an infection develops, monitor carefully, and stop etanercept if the infection becomes serious.
  • Consider empiric anti-fungal therapy for patients at risk (those who reside in or travel to regions where mycoses are endemic) for invasive fungal infections who develop a severe systemic illness on etanercept.
  • Demyelinating disease, exacerbation or new onset, may occur.
  • Cases of lymphoma have been observed in patients receiving TNFi’s.
  • Congestive heart failure, worsening or new onset, may occur.
  • Advise patients to seek immediate medical attention if symptoms of pan­cytopenia or aplastic anemia develop, and consider stopping etanercept.
  • Monitor HBV carriers for reactivation during and following therapy. If reactivation occurs, consider stopping etanercept and beginning anti-viral therapy.
  • Anaphylaxis or serious allergic reactions may occur.
  • Stop etanercept if lupus-like syndrome or autoimmune hepatitis develops.

Dosage & Administration

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Etanercept is administered by subcutaneous injection.

Adults: The starting dose is 50 mg twice weekly for three months. The maintenance dose is 50 mg once weekly.

Pediatrics:

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  • 63 kg (138 lbs.) or more: the recommended dose is 50 mg weekly.
  • Less than 63 kg (138 lbs.): the recommended dose is 0.8 mg/kg weekly.

Commentary: Etanercept is approved for adult and pediatric plaque psoriasis. It is the first and only systemic therapy to treat children aged 4-17 years for chronic moderate to severe plaque psoriasis. The most common adverse reactions (≥5%) are infections and injection-site reactions.

Infliximab (Remicade):16 infusion

Biosimilar(s): Infliximab-dyyb (Inflectra),17 Infliximab-abda (Renflexis),18 Infliximab-qbtx (Ixifi)19

Drug class: DMARD, TNFi

Boxed warning: Refer to *ISI (above) and

  • Fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNFi’s, post­marketing. All infliximab cases occurred in IBD patients, who were mostly adolescent or young adult males. All had received azathioprine or 6-mercaptopurine concomitantly with infliximab at or prior to diagnosis.

Warnings & Precautions

  • Do not give infliximab during an active infection. If an infection develops, monitor carefully and stop infliximab if the infection becomes serious.
  • Invasive fungal infections—for patients who develop a systemic illness on infliximab, consider empiric anti-fungal therapy for those who reside or travel to regions where mycoses are endemic
  • The incidence of malignancies, including lymphoma, was greater in infliximab-treated patients than in controls. Due to the risk of HSTCL, carefully assess the risk/benefit especially in IBD patients, in males, and if receiving azathioprine or 6-mercaptopurine treatment.
  • HBV reactivation can occur. Test for HBV infection before starting infliximab. Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop infliximab and begin anti-viral therapy.
  • Hepatotoxicity—rare severe hepatic reactions, some fatal or necessitating liver transplantation have occurred. Stop infliximab in cases of jaundice and/or marked liver enzyme elevations.
  • Heart failure, new onset or worsening symptoms, may occur.
  • Cytopenias—advise patients to seek immediate medical attention if signs and symptoms develop, and consider stopping infliximab.
  • Hypersensitivity—serious infusion reactions including anaphylaxis or serum sickness-like reactions may occur.
  • Demyelinating disease, exacerbation or new onset, may occur.
  • Lupus-like syndrome—stop infliximab if syndrome develops.
  • Live vaccines or therapeutic infectious agents should not be given with infliximab.

Dosage & Administration

Infliximab is administered by intravenous infusion over a period of not less than two hours. The recommended dose is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks, followed by a maintenance regimen of 5 mg/kg every eight weeks.

Commentary: The FDA approved infliximab for treatment of psoriasis based on data from two multicenter clinical trials that enrolled 1,200 patients. The results showed that a majority of infliximab-treated patients achieved clinically significant levels of skin clearance with induction and every-eight-week maintenance therapy. The most common adverse reactions (≥10%) are infections (e.g., upper respiratory, sinusitis, pharyngitis), infusion-related reactions, headache and abdominal pain.

Pages: 1 2 3 4 5 6 7 8 | Single Page

Filed Under: Conditions, Drug Updates Tagged With: adalimumab, apremilast, brodalumab, Certolizumab Pegol, etanercept, guselkumab, guttate psoriasis, infliximab, inverse psoriasis, ixekizumab, Psoriatic Arthritis, psoriatic erythroderma, pustular psoriasis, Rheumatic Drugs at a Glance, secukinumab, tildrakizumab, ustekinumab, vulgar psoriasisIssue: May 2019

You Might Also Like:
  • Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis
  • Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis
  • Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4
  • Rheumatology Drug Updates: Etanercept for Pediatric Plaque Psoriasis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)